Oncolytic viruses: The best is yet to come

Current Cancer Drug Targets

Volumn 18, Issue 2, 2018, Pages 109-123

  Lemay, Chantal G ^a   Keller, Brian A ^a,b   Edge, Robert E ^a   Abei, Masato ^c   Bell, John C ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cancer therapy; Combination therapy; Immunity; Oncolytic viruses; Tumour microenvironment; Virotherapy

Indexed keywords

CHECKPOINT KINASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS;

ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CARCINOGENESIS; CELL HOMING; CELL KILLING; CELL PROLIFERATION; CYTOTOXICITY; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MESENCHYMAL STEM CELL; MICROMETASTASIS; NEOVASCULARIZATION (PATHOLOGY); NERVOUS SYSTEM INFLAMMATION; NEUROBLASTOMA; ONCOLYTIC VIROTHERAPY; REVIEW; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT; ANIMAL; GENETICS; NEOPLASM;

ANIMALS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 85026610084     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009617666170206111609     Document Type: Review

References (244)

1. Evgin, L.; Acuna, S.A.; Tanese de Souza, C.; Marguerie, M.; Lemay, C.G.; Ilkow, C.S.; Findlay, C.S.; Falls, T.; Parato, K.A.; Hanwell, D.; Goldstein, A.; Lopez, R.; Lafrance, S.; Breitbach, C.J.; Kirn, D.; Atkins, H.; Auer, R.C.; Thurman, J.M.; Stahl, G.L.; Lambris, J.D.; Bell, J.C.; McCart, J.A. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol. Ther., 2015, 23, 1066-1076.
2. Power, A.T.; Wang, J.; Falls, T.J.; Paterson, J.M.; Parato, K.A.; Lichty, B.D.; Stojdl, D.F.; Forsyth, P.A.J.; Atkins, H.; Bell, J.C. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther., 2007, 15, 123-130.
3. Liu, C.; Russell, S.J.; Peng, K.-W. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol. Ther., 2010, 18, 1155-1164.
4. Mader, E.K.; Maeyama, Y.; Lin, Y.; Butler, G.W.; Russell, H.M.; Galanis, E.; Russell, S.J.; Dietz, A.B.; Peng, K.W. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin. Cancer Res., 2009, 15, 7246-7255.
5. Ilett, E.J.; Bárcena, M.; Errington-Mais, F.; Griffin, S.; Harrington, K.J.; Pandha, H.S.; Coffey, M.; Selby, P.J.; Limpens, R.W.A.L.; Mommaas, M.; Hoeben, R.C.; Vile, R.G.; Melcher, A.A. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin. Cancer Res., 2011, 17, 2767-2776.
6. Alcayaga-Miranda, F.; Cascallo, M.; Rojas, J.J.; Pastor, J.; Alemany, R. Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies. Cancer Gene Ther., 2010, 17, 792-802.
7. Peng, K.; Dogan, A.; Vrana, J.; Liu, C.; Ong, H.T.; Kumar, S.; Dispenzieri, A.; Dietz, A.B.; Russell, S.J. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am. J. Hematol., 2009, 84, 401-407.
8. Muthana, M.; Giannoudis, A.; Scott, S.D.; Fang, H.-Y.Y.; Coffelt, S.B.; Morrow, F.J.; Murdoch, C.; Burton, J.; Cross, N.; Burke, B.; Mistry, R.; Hamdy, F.; Brown, N.J.; Georgopoulos, L.; Hoskin, P.; Essand, M.; Lewis, C.E.; Maitland, N.J. Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res., 2011, 71, 1805-1815.
9. Muthana, M.; Rodrigues, S.; Chen, Y.Y.; Welford, A.; Hughes, R.; Tazzyman, S.; Essand, M.; Morrow, F.; Lewis, C.E. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. Cancer Res., 2013, 73, 490-495.
10. García-Gómez, I.; Elvira, G.; Zapata, A.G.; Lamana, M.L.; Ramírez, M.; Castro, J.G.; Arranz, M.G.; Vicente, A.; Bueren, J.; García-Olmo, D. Mesenchymal stem cells: Biological properties and clinical applications. Expert Opin. Biol. Ther., 2010, 10, 1453-1468.
11. Mader, E.K.; Butler, G.; Dowdy, S.C.; Mariani, A.; Knutson, K.L.; Federspiel, M.J.; Russell, S.J.; Galanis, E.; Dietz, A.B.; Peng, K.-W. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase i clinical trial in ovarian cancer. J. Transl. Med., 2013, 11, 20.
12. Yong, R.L.; Shinojima, N.; Fueyo, J.; Gumin, J.; Vecil, G.G.; Marini, F.C.; Bogler, O.; Andreeff, M.; Lang, F.F. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus delta24-rgd to human gliomas. Cancer Res., 2009, 69, 8932-8940.
13. Hsiao, W.-C.; Sung, S.-Y.; Liao, C.-H.; Wu, H.-C.; Hsieh, C.-L. Vitamin d(3)-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth. Mol. Pharm., 2012, 9, 1396-1408.
14. Duebgen, M.; Martinez-Quintanilla, J.; Tamura, K.; Hingtgen, S.; Redjal, N.; Wakimoto, H.; Shah, K. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J. Natl. Cancer Inst., 2014, 106, dju090.
15. García-Castro, J.; Alemany, R.; Cascalló, M.; Martínez-Quintanilla, J.; Arriero, M.D.M.; Lassaletta, A.; Madero, L.; Ramírez, M. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther., 2010, 17, 476-483.
16. Ahmed, A.U.; Tyler, M.A.; Thaci, B.; Alexiades, N.G.; Han, Y.; Ulasov, I.V; Lesniak, M.S. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol. Pharm., 2011, 8, 1559-1572.
17. Thaci, B.; Ahmed, A.U.; Ulasov, I.V; Tobias, A.L.; Han, Y.; Aboody, K.S.; Lesniak, M.S. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther., 2012, 19, 431-442.
18. Qiao, J.; Kottke, T.; Willmon, C.; Galivo, F.; Wongthida, P.; Diaz, R.M.; Thompson, J.; Ryno, P.; Barber, G.N.; Chester, J.; Selby, P.; Harrington, K.; Melcher, A.; Vile, R.G. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive t cell therapy, oncolytic virotherapy and immunotherapy. Nat. Med., 2008, 14, 37-44.
19. Ong, H.T.; Hasegawa, K.; Dietz, A.B.; Russell, S.J.; Peng, K.-W. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther., 2007, 14, 324-333.
20. Hershkovitz, L.; Schachter, J.; Treves, A.J.; Besser, M.J. Focus on adoptive T cell transfer trials in melanoma. Clin. Dev. Immunol., 2010, 1-11.
21. Gil, M.; Bieniasz, M.; Wierzbicki, A.; Bambach, B.J.; Rokita, H.; Kozbor, D. Targeting a mimotope vaccine to activating fcgamma receptors empowers dendritic cells to prime specific cd8+ t cell responses in tumor-bearing mice. J. Immunol., 2009, 183, 6808-6818.
22. Thorne, S.H.; Negrin, R.S.; Contag, C.H. Synergistic antitumor effects of immune cell-viral biotherapy. Science, 2006, 311, 1780-1784.
23. Tang, H.; Sampath, P.; Yan, X.; Thorne, S.H. Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination. Gene Ther., 2013, 20, 770-778.
24. Sampath, P.; Li, J.; Hou, W.; Chen, H.; Bartlett, D.L.; Thorne, S.H. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol. Ther., 2013, 21, 620-628.
25. Moserle, L.; Amadori, A.; Indraccolo, S. The angiogenic switch: Implications in the regulation of tumor dormancy. Curr. Mol. Med., 2009, 9, 935-941.
26. Dvorak, H.F.; Weaver, V.M.; Tlsty, T.D.; Bergers, G. Tumor microenvironment and progression access. J. Surg. Oncol., 2012, 103, 468-474.
27. Jain, R.K. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat. Rev. Cancer, 2008, 8, 309-316.
28. Ribatti, D. Endogenous inhibitors of angiogenesis. A historical review. Leuk. Res., 2009, 33, 638-644.
29. Fang, L.; Pu, Y.-Y.; Hu, X.-C.; Sun, L.-J.; Luo, H.-M.; Pan, S.-K.; Gu, J.-Z.; Cao, X.-R.; Su, C.-Q. Antiangiogenesis gene armed tumor-targeting adenovirus yields multiple antitumor activities in human hcc xenografts in nude mice. Hepatol. Res., 2010, 40, 216-228.
30. Tysome, J.R.; Wang, P.; Alusi, G.; Briat, A.; Gangeswaran, R.; Wang, J.; Bhakta, V.; Fodor, I.; Lemoine, N.R.; Wang, Y. Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: An oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer. Hum. Gene Ther., 2011, 22, 1101-1108.
31. Tysome, J.R.; Briat, A.; Alusi, G.; Cao, F.; Gao, D.; Yu, J.; Wang, P.; Yang, S.; Dong, Z.; Wang, S.; Deng, L.; Francis, J.; Timiryasova, T.; Fodor, I.; Lemoine, N.R.; Wang, Y. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther., 2009, 16, 1223-1233.
32. Zhang, G.; Jin, G.; Nie, X.; Mi, R.; Zhu, G.; Jia, W.; Liu, F. Enhanced antitumor efficacy of an oncolytic herpes simplex virus expressing an endostatin-angiostatin fusion gene in human glioblastoma stem cell xenografts. PLoS One, 2014, 9, e95872.
33. Li, L.; Zhang, Y.; Zhou, L.; Ke, M.; Chen, J.; Fu, X.; Ye, C.; Wu, J.; Liu, R.; Huang, W. Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells. J. Transl. Med., 2013, 11, 257.
34. Goodwin, J.M.; Schmitt, A.D.; McGinn, C.M.; Fuchs, B.C.; Kuruppu, D.; Tanabe, K.K.; Lanuti, M. Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model. Cancer Invest., 2012, 30, 243-250.
35. Hutzen, B.; Bid, H.K.; Houghton, P.J.; Pierson, C.R.; Powell, K.; Bratasz, A.; Raffel, C.; Studebaker, A.W. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin. BMC Cancer, 2014, 14, 206.
36. Xiao, T.; Fan, J.K.; Huang, H.L.; Gu, J.F.; Li, L.-Y.; Liu, X.Y. VEGI-Armed oncolytic adenovirus inhibits tumor neovascu-larization and directly induces mitochondria-mediated cancer cell apoptosis. Cell Res., 2010, 20, 367-378.
37. Guse, K.; Sloniecka, M.; Diaconu, I.; Ottolino-Perry, K.; Tang, N.; Ng, C.; Le Boeuf, F.; Bell, J.C.; McCart, J.A.; Ristimäki, A.; Pesonen, S.; Cerullo, V.; Hemminki, A. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J. Virol., 2010, 84, 856-866.
38. Frentzen, A.; Yu, Y.A.; Chen, N.; Zhang, Q.; Weibel, S.; Raab, V.; Szalay, A.A. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 12915-12920.
39. Yang, S.W.; Cody, J.J.; Rivera, A.A; Waehler, R.; Wang, M.; Kimball, K.J.; Alvarez, R. A; Siegal, G.P.; Douglas, J.T.; Ponnazhagan, S. Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy. Clin. Cancer Res., 2011, 17, 538-549.
40. Hardcastle, J.; Kurozumi, K.; Dmitrieva, N.; Sayers, M.P.; Ahmad, S.; Waterman, P.; Weissleder, R.; Chiocca, E.A.; Kaur, B. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol. Ther., 2010, 18, 285-294.
41. Fujii, K.; Kurozumi, K.; Ichikawa, T.; Onishi, M.; Shimazu, Y.; Ishida, J.; Chiocca, E.A.; Kaur, B.; Date, I. The Integrin Inhibitor Cilengitide Enhances the Anti-Glioma Efficacy of vasculostatin-expressing oncolytic virus. Cancer Gene Ther., 2013, 20, 437-444.
42. Libertini, S.; Lacuzzo, I.; Perruolo, G.; Scala, S.; Leranò, C.; Franco, R.; Hallden, G.; Portella, G. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus d/922-947. Clin. Cancer Res., 2008, 14, 6505-6514.
43. Zhang, W.; Fulci, G.; Buhrman, J.S.; Stemmer-Rachamimov, A.O.; Chen, J.W.; Wojtkiewicz, G.R.; Weissleder, R.; Rabkin, S.D.; Martuza, R.L. Bevacizumab with angiostatin-armed OHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol. Ther., 2012, 20, 37-45.
44. Breitbach, C.J.; Arulanandam, R.; De Silva, N.; Thorne, S.H.; Patt, R.; Daneshmand, M.; Moon, A.; Ilkow, C.; Burke, J.; Hwang, T.H.; Heo, J.; Cho, M.; Chen, H.; Angarita, F.A.; Addison, C.; McCart, J.A.; Bell, J.C.; Kirn, D.H. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res., 2013, 73, 1265-1275.
45. Tseng, J.-C.; Granot, T.; DiGiacomo, V.; Levin, B.; Meruelo, D. Enhanced specific delivery and targeting of oncolytic sindbis viral vectors by modulating vascular leakiness in tumor. Cancer Gene Ther., 2010, 17, 244-255.
46. Kottke, T.; Hall, G.; Pulido, J.; Diaz, R.M.; Thompson, J.; Chong, H.; Selby, P.; Coffey, M.; Pandha, H.; Chester, J.; Melcher, A.; Harrington, K.; Vile, R. Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J. Clin. Invest., 2010, 120, 1551-1560.
47. Arulanandam, R.; Batenchuk, C.; Angarita, F.A.; Ottolino-Perry, K.; Cousineau, S.; Mottashed, A.; Burgess, E.; Falls, T.J.; De Silva, N.; Tsang, J.; Howe, G.A.; Bourgeois-Daigneault, M.-C.; Conrad, D.P.; Daneshmand, M.; Breitbach, C.J.; Kirn, D.H.; Raptis, L.; Sad, S.; Atkins, H.; Huh, M.S.; Diallo, J.-S.; Lichty, B.D.; Ilkow, C.S.; Le Boeuf, F.; Addison, C.L.; McCart, J.A.; Bell, J.C. VEGF-Mediated induction of PRD1-BF1/BLIMP1 expression sensitizes tumor vasculature to oncolytic virus infection. Cancer Cell, 2015, 28, 210-224.
48. Saito, Y.; Sunamura, M.; Motoi, F.; Abe, H.; Egawa, S.; Duda, D.G.; Hoshida, T.; Fukuyama, S.; Hamada, H.; Matsuno, S. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1a region. Cancer Gene Therapy, 2006, 13, 242-252.
49. Breitbach, C.J.; Paterson, J.M.; Lemay, C.G.; Falls, T.J.; McGuire, A.; Parato, K.A.; Stojdl, D.F.; Daneshmand, M.; Speth, K.; Kirn, D.; McCart, J.A.; Atkins, H.; Bell, J.C. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther., 2007, 15, 1686-1693.
50. Breitbach, C.J.; De Silva, N.S.; Falls, T.J.; Aladl, U.; Evgin, L.; Paterson, J.; Sun, Y.Y.; Roy, D.G.; Rintoul, J.L.; Daneshmand, M.; Parato, K.; Stanford, M.M.; Lichty, B.D.; Fenster, A.; Kirn, D.; Atkins, H.; Bell, J.C. Targeting tumor vasculature with an oncolytic virus. Mol. Ther., 2011, 19, 886-894.
51. Liu, T.-C.; Hwang, T.; Park, B.-H.; Bell, J.; Kirn, D.H. The targeted oncolytic poxvirus jx-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol. Ther., 2008, 16, 1637-1642.
52. Heo, J.; Breitbach, C.J.; Moon, A.; Kim, C.W.; Patt, R.; Kim, M.K.; Lee, Y.K.; Oh, S.Y.; Woo, H.Y.; Parato, K.; Rintoul, J.; Falls, T.; Hickman, T.; Rhee, B.-G.; Bell, J.C.; Kirn, D.H.; Hwang, T.-H. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol. Ther., 2011, 19, 1170-1179.
53. Kim, J.; Nam, H.Y.; Kim, T. Il; Kim, P.H.; Ryu, J.; Yun, C.O.; Kim, S.W. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA. Biomaterials, 2011, 32, 5158-5166.
54. Kim, J.; Nam, H.Y.; Choi, J.W.; Yun, C.-O.; Kim, S.W. Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer. Gene Ther., 2014, 21, 476-483.
55. Tyler, M.A; Ulasov, I.V; Borovjagin, A.; Sonabend, A.M.; Khramtsov, A.; Han, Y.; Dent, P.; Fisher, P.B.; Curiel, D.T.; Lesniak, M.S. Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD Fiber-modified adenovirus. Mol. Cancer Ther., 2006, 5, 2408-2416.
56. Ong, H.T.; Trejo, T.R.; Pham, L.D.; Oberg, A.L.; Russell, S.J.; Peng, K.-W. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in Vivo. Mol. Ther. J. Am. Soc. Gene Ther., 2009, 17, 1012-1021.
57. Gamble, L.J.; Ugai, H.; Wang, M.; Borovjagin, A.V; Matthews, Q.L. Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and fiber, Δ24DoubleRGD, in an ovarian cancer model. J. Mol. Biochem., 2012, 1, 26-39.
58. Rojas, J.J.; Gimenez-Alejandre, M.; Gil-Hoyos, R.; Cascallo, M.; Alemany, R. Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD. Gene Ther, 2012, 19, 453-457.
59. Pesonen, S.; Diaconu, I.; Cerullo, V.; Escutenaire, S.; Raki, M.; Kangasniemi, L.; Nokisalmi, P.; Dotti, G.; Guse, K.; Laasonen, L.; Partanen, K.; Karli, E.; Haavisto, E.; Oksanen, M.; Karioja-Kallio, A.; Hannuksela, P.; Holm, S.-L.L.; Kauppinen, S.; Joensuu, T.; Kanerva, A.; Hemminki, A. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int. J. Cancer, 2012, 130, 1937-1947.
60. Wang, H.; Cai, Z.; Yang, F.; Luo, J.; Satoh, M.; Arai, Y.; Li, D. Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer. Urology, 2014, 83, 508.e13-e508.e19.
61. Hallak, L.K.; Merchan, J.R.; Storgard, C.M.; Loftus, J.C.; Russell, S.J. Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res., 2005, 65, 5292-5300.
62. Ammayappan, A.; Peng, K.-W.; Russell, S.J. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands. J. Virol., 2013, 87, 13543-13555.
63. Chen, H.H.; Cawood, R.; El-Sherbini, Y.; Purdie, L.; Bazan-Peregrino, M.; Seymour, L.W.; Carlisle, R.C. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia. Mol. Ther., 2011, 19, 67-75.
64. Kim, S.H.; Turnbull, J.; Guimond, S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J. Endocrinol., 2011, 209, 139-151.
65. Jain, R.K.; Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol., 2010, 7, 653-664.
66. Voros, A.; Kormos, B.; Valyi-Nagy, T.; Valyi-Nagy, K. Increased resistance of breast, prostate, and embryonic carcinoma cells against herpes simplex virus in three-dimensional cultures. ISRN Oncol., 2013, 2013, 104913.
67. Maillard, L.; Ziol, M.; Tahlil, O.; Le Feuvre, C.; Feldman, L.J.; Branellec, D.; Bruneval, P.; Steg, P. Pre-Treatment with elastase improves the efficiency of percutaneous adenovirus-mediated gene transfer to the arterial media. Gene Ther., 1998, 5, 1023-1030.
68. Kuriyama, N.; Kuriyama, H.; Julin, C.M.; Lamborn, K.; Israel, M.A. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum. Gene Ther., 2000.
69. Lee, S.Y.; Park, H.R.; Rhee, J.; Park, Y.M.; Kim, S.-H. Therapeutic effect of oncolytic adenovirus expressing relaxin in radioresistant oral squamous cell carcinoma. Oncol. Res., 2013, 20, 419-425.
70. Kim, J.-H.; Lee, Y.-S.; Kim, H.; Huang, J.-H.; Yoon, A.-R.; Yun, C.-O. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J. Natl. Cancer Inst., 2006, 98, 1482-1493.
71. Ganesh, S.; Gonzalez Edick, M.; Idamakanti, N.; Abramova, M.; Vanroey, M.; Robinson, M.; Yun, C.-O.; Jooss, K. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res., 2007, 67, 4399-4407.
72. Cheng, J.; Sauthoff, H.; Huang, Y.; Kutler, D.I.; Bajwa, S.; Rom, W.N.; Hay, J.G. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol. Ther., 2007, 15, 1982-1990.
73. McKee, T.D.; Grandi, P.; Mok, W.; Alexandrakis, G.; Insin, N.; Zimmer, J.P.; Bawendi, M.G.; Boucher, Y.; Breakefield, X.O.; Jain, R.K. degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res., 2006, 66, 2509-2513.
74. Yaacov, B.; Lazar, I.; Tayeb, S.; Frank, S.; Izhar, U.; Lotem, M.; Perlman, R.; Ben-Yehuda, D.; Zakay-Rones, Z.; Panet, A. Extracellular matrix constituents interfere with newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity. J. Gen. Virol., 2012, 93, 1664-1672.
75. Mok, W.; Boucher, Y.; Jain, R.K. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res., 2007, 67, 10664-10668.
76. Haseley, A.; Boone, S.; Wojton, J.; Yu, L.; Yoo, J.Y.; Yu, J.; Kurozumi, K.; Glorioso, J.C.; Caligiuri, M.A.; Kaur, B. Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Res., 2012, 72, 1353-1362.
77. Hong, C.-S.; Fellows, W.; Niranjan, A; Alber, S.; Watkins, S.; Cohen, J.B.; Glorioso, J.C.; Grandi, P. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther., 2010, 17, 1200-1205.
78. Schaefer, S.; Weibel, S.; Donat, U.; Zhang, Q.; Aguilar, R.J.; Chen, N.G.; Szalay, A.A. Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors. BMC Cancer, 2012, 12, 366.
79. Ganesh, S.; Gonzalez-Edick, M.; Gibbons, D.; Van Roey, M.; Jooss, K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin. Cancer Res., 2008, 14, 3933-3941.
80. Guedan, S.; Rojas, J.J.; Gros, A.; Mercade, E.; Cascallo, M.; Alemany, R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol. Ther., 2010, 18, 1275-1283.
81. Choi, I.-K.; Lee, Y.-S.; Yoo, J.Y.; Yoon, A-R.; Kim, H.; Kim, D.-S.; Seidler, D.G.; Kim, J.-H.; Yun, C.-O. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther., 2010, 17, 190-201.
82. Dmitrieva, N.; Yu, L.; Viapiano, M.; Cripe, T.P.; Chiocca, E.A.; Glorioso, J.C.; Kaur, B. Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin. Cancer Res., 2011, 17, 1362-1372.
83. Heneberg, P. Critical reviews in oncology/ hematology paracrine tumor signaling induces transdifferentiation of surrounding fibroblasts. 2016, 97, 303-311.
84. Ilkow, C.S.; Marguerie, M.; Batenchuk, C.; Mayer, J.; Ben Neriah, D.; Cousineau, S.; Falls, T.; Jennings, V.A.; Boileau, M.; Bellamy, D.; Bastin, D.; de Souza, C.T.; Alkayyal, A.; Zhang, J.; Le Boeuf, F.; Arulanandam, R.; Stubbert, L.; Sampath, P.; Thorne, S.H.; Paramanthan, P.; Chatterjee, A.; Strieter, R.M.; Burdick, M.; Addison, C.L.; Stojdl, D.F.; Atkins, H.L.; Auer, R.C.; Diallo, J.-S.; Lichty, B.D.; Bell, J.C. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat. Med., 2015, 21, 530-536.
85. Diop-Frimpong, B.; Chauhan, V.P.; Krane, S.; Boucher, Y.; Jain, R.K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. USA, 2011, 108, 2909-2914.
86. Naik, P.; Murumkar, P.; Giridhar, R.; Yadav, M.R. Angiotensin II Receptor Type 1 (AT1) selective nonpeptidic antagonists--a perspective. Bioorg. Med. Chem., 2010, 18, 8418-8456.
87. Brekken, C.; Bruland, Ø.S.; de Lange Davies, C. Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase. Anticancer Res., 2000, 20, 3503-3512.
88. Whitmire, J.K. Induction and function of virus-specific CD4+ T cell responses. Virology, 2011, 411, 216-228.
89. Naik, J.D.; Twelves, C.J.; Selby, P.J.; Vile, R.G.; Chester, J.D. Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin. Cancer Res., 2011, 17, 4214-4224.
90. Errington, F.; Steele, L.; Prestwich, R.; Harrington, K.J.; Pandha, H.S.; Vidal, L.; de Bono, J.; Selby, P.; Coffey, M.; Vile, R.; Melcher, A. Reovirus activates human dendritic cells to promote innate antitumor immunity. J. Immunol., 2008, 180, 6018-6026.
91. Prestwich, R.J.; Errington, F.; Ilett, E.J.; Morgan, R.S.M.; Scott, K.J.; Kottke, T.; Thompson, J.; Morrison, E.E.; Harrington, K.J.; Pandha, H.S.; Selby, P.J.; Vile, R.G.; Melcher, A.A. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin. Cancer Res., 2008, 14, 7358-7366.
92. Gauvrit, A.; Brandler, S.; Sapede-Peroz, C.; Boisgerault, N.; Tangy, F.; Gregoire, M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res., 2008, 68, 4882-4892.
93. Ilett, E.J.; Prestwich, R.J.; Kottke, T.; Errington, F.; Thompson, J.M.; Harrington, K.J.; Pandha, H.S.; Coffey, M.; Selby, P.J.; Vile, R.G.; Melcher, A. A. Dendritic Cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther., 2009, 16, 689-699.
94. Boudreau, J.E.; Bridle, B.W.; Stephenson, K.B.; Jenkins, K.M.; Brunellière, J.; Bramson, J.L.; Lichty, B.D.; Wan, Y. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol. Ther., 2009, 17, 1465-1472.
95. Gujar, S.A.; Marcato, P.; Pan, D.; Lee, P.W.K. Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol. Cancer Ther., 2010, 9, 2924-2933.
96. Workenhe, S.T.; Simmons, G.; Pol, J.G.; Lichty, B.D.; Halford, W.P.; Mossman, K.L. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol. Ther., 2014, 22, 123-131.
97. Sobol, P.T.; Boudreau, J.E.; Stephenson, K.; Wan, Y.; Lichty, B.D.; Mossman, K.L. Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol. Ther., 2011, 19, 335-344.
98. Diaz, R.M.; Galivo, F.; Kottke, T.; Wongthida, P.; Qiao, J.; Thompson, J.; Valdes, M.; Barber, G.; Vile, R.G. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res., 2007, 67, 2840-2848.
99. Prestwich, R.J.; Errington, F.; Steele, L.P.; Ilett, E.J.; Morgan, R.S.M.; Harrington, K.J.; Pandha, H.S.; Selby, P.J.; Vile, R.G.; Melcher, A.A. Reciprocal Human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J. Immunol., 2009, 183, 4312-4321.
100. Gujar, S.A.; Pan, D.A.; Marcato, P.; Garant, K.A.; Lee, P.W.K. Oncolytic virus-initiated protective immunity against prostate cancer. Mol. Ther., 2011, 19, 797-804.
101. Steele, L.; Errington, F.; Prestwich, R.; Ilett, E.; Harrington, K.; Pandha, H.; Coffey, M.; Selby, P.; Vile, R.; Melcher, A. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is pkr/nf-κb mediated and supports innate and adaptive anti-tumour immune priming. Mol. Cancer, 2011, 10, 20.
102. Jarahian, M.; Watzl, C.; Fournier, P.; Arnold, A.; Djandji, D.; Zahedi, S.; Cerwenka, A.; Paschen, A.; Schirrmacher, V.; Momburg, F. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J. Virol., 2009, 83, 8108-8121.
103. Wongthida, P.; Diaz, R.M.; Galivo, F.; Kottke, T.; Thompson, J.; Pulido, J.; Pavelko, K.; Pease, L.; Melcher, A.; Vile, R. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res., 2010, 70, 4539-4549.
104. Boudreau, J.E.; Stephenson, K.B.; Wang, F.; Ashkar, A. a.; Mossman, K.L.; Lenz, L.L.; Rosenthal, K.L.; Bramson, J.L.; Lichty, B.D.; Wan, Y. IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res., 2011, 71, 2497-2506.
105. Bhat, R.; Dempe, S.; Dinsart, C.; Rommelaere, J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int. J. Cancer, 2011, 128, 908-919.
106. Chisholm, S.E.; Reyburn, H.T. Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors. J. Virol., 2006, 80, 2225-2233.
107. Ogbomo, H.; Zemp, F.J.; Lun, X.; Zhang, J.; Stack, D.; Rahman, M.M.; McFadden, G.; Mody, C.H.; Forsyth, P.A. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo. PLoS One, 2013, 8, e66825.
108. Zhang, J.; Tai, L.-H.; Ilkow, C.S.; Alkayyal, A.A.; Ananth, A.A.; de Souza, C.T.; Wang, J.; Sahi, S.; Ly, L.; Lefebvre, C.; Falls, T.J.; Stephenson, K.B.; Mahmoud, A.B.; Makrigiannis, A.P.; Lichty, B.D.; Bell, J.C.; Stojdl, D.F.; Auer, R.C. Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. Mol. Ther., 2014, 22, 1320-1332.
109. Ramsburg, E.; Publicover, J.; Buonocore, L.; Poholek, A.; Robek, M.; Palin, A.; Rose, J.K. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J. Virol., 2005, 79, 15043-15053.
110. Grossardt, C.; Engeland, C.E.; Bossow, S.; Halama, N.; Zaoui, K.; Leber, M.F.; Springfeld, C.; Jaeger, D.; von Kalle, C.; Ungerechts, G. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum. Gene Ther., 2013, 24, 644-654.
111. Janke, M.; Peeters, B.; de Leeuw, O.; Moorman, R.; Arnold, A; Fournier, P.; Schirrmacher, V. Recombinant newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther., 2007, 14, 1639-1649.
112. Kohno, S.-I.; Luo, C.; Nawa, A; Fujimoto, Y.; Watanabe, D.; Goshima, F.; Tsurumi, T.; Nishiyama, Y. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther., 2007, 14, 918-926.
113. Malhotra, S.; Kim, T.; Zager, J.; Bennett, J.; Ebright, M.; D’Angelica, M.; Fong, Y. Use of an oncolytic virus secreting gm-csf as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery, 2007, 141, 520-529.
114. Thorne, S.H.; Hwang, T.H.H.; O’Gorman, W.E.; Bartlett, D.L.; Sei, S.; Kanji, F.; Brown, C.; Werier, J.; Cho, J.H.; Lee, D.E.; Wang, Y.; Bell, J.; Kirn, D.H. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest., 2007, 117, 3350-3358.
115. Lei, N.; Shen, F.B.; Chang, J.H.; Wang, L.; Li, H.; Yang, C.; Li, J.; Yu, D.C. An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors. Cancer Gene Ther., 2009, 16, 33-43.
116. Burke, J.M.; Lamm, D.L.; Meng, M. V.; Nemunaitis, J.J.; Stephenson, J.J.; Arseneau, J.C.; Aimi, J.; Lerner, S.; Yeung, A.W.; Kazarian, T.; Maslyar, D.J.; McKiernan, J.M. A first in human phase 1 study of cg0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J. Urol., 2012, 188, 2391-2397.
117. Kanerva, A.; Nokisalmi, P.; Diaconu, I.; Koski, A.; Cerullo, V.; Liikanen, I.; Tähtinen, S.; Oksanen, M.; Heiskanen, R.; Pesonen, S.; Joensuu, T.; Alanko, T.; Partanen, K.; Laasonen, L.; Kairemo, K.; Pesonen, S.; Kangasniemi, L.; Hemminki, A. Antiviral and antitumor t-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin. Cancer Res., 2013, 19, 2734-2744.
118. Lemay, C.G.; Rintoul, J.L.; Kus, A.; Paterson, J.M.; Garcia, V.; Falls, T.J.; Ferreira, L.; Bridle, B.W.; Conrad, D.P.; Tang, V.A.; Diallo, J.-S.; Arulanandam, R.; Le Boeuf, F.; Garson, K.; Vanderhyden, B.C.; Stojdl, D.F.; Lichty, B.D.; Atkins, H.L.; Parato, K.A.; Bell, J.C.; Auer, R.C. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol. Ther., 2012, 20, 1791-1799.
119. Sanlorenzo, M.; Vujic, I.; Posch, C.; Dajee, A.; Yen, A.; Kim, S.; Ashworth, M.; Rosenblum, M.D.; Algazi, A.; Osella-Abate, S.; Quaglino, P.; Daud, A.; Ortiz-Urda, S. Melanoma immunotherapy. Cancer Biol. Ther., 2014, 15, 665-674.
120. Choi, I.-K.; Lee, J.-S.; Zhang, S.-N.; Park, J.; Sonn, C.H.; Lee, K.-M.; Yun, C.-O. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα. Gene Ther., 2011, 18, 898-909.
121. Shin, E.J.; Wanna, G.B.; Choi, B.; Aguila, D.; Ebert, O.; Genden, E.M.; Woo, S.L. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma. Laryngoscope, 2007, 117, 210-214.
122. Ino, Y.; Saeki, Y.; Fukuhara, H.; Todo, T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin. Cancer Res., 2006, 12, 643-652.
123. Bai, F.; Niu, Z.; Tian, H.; Li, S.; Lv, Z.; Zhang, T.; Ren, G.; Li, D. Genetically engineered newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy. Immunol. Lett., 2014, 159, 36-46.
124. Lapteva, N.; Aldrich, M.; Weksberg, D.; Rollins, L.; Goltsova, T.; Chen, S.-Y.; Huang, X.F. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing rantes elicits potent antitumor immunity. J. Immunother., 2009, 32, 145-156.
125. Li, J.; O’Malley, M.; Urban, J.; Sampath, P.; Guo, Z.S.; Kalinski, P.; Thorne, S.H.; Bartlett, D.L. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol. Ther., 2011, 19, 650-657.
126. Ramakrishna, E.; Woller, N.; Mundt, B.; Knocke, S.; Gurlevik, E.; Saborowski, M.; Malek, N.; Manns, M.P.; Wirth, T.C.; Kuhnel, F.; Kubicka, S.; Edukulla, R.; Ramakrishna, E.; Woller, N.; Mundt, B.; Knocke, S.; Gürlevik, E.; Saborowski, M.; Malek, N.; Manns, M.P.; Wirth, T.C.; Kühnel, F.; Kubicka, S.; Gurlevik, E.; Saborowski, M.; Malek, N.; Manns, M.P.; Wirth, T.C.; Kuhnel, F.; Kubicka, S. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res., 2009, 69, 1448-1458.
127. Li, J.; O’Malley, M.; Sampath, P.; Kalinski, P.; Bartlett, D.L.; Thorne, S.H. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia, 2012, 14, 1115-1121.
128. Miller, J.; Bidula, S.M.; Jensen, T.M.; Reiss, C.S. Cytokine-modified VSV is attenuated for neural pathology, but is both highly immunogenic and oncolytic. Int. J. Infereron. Cytokine Mediator Res., 2009, 1, 15-32.
129. Choi, I.-K.; Li, Y.; Oh, E.; Kim, J.; Yun, C.-O. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-Co-producing T cell-mediated antitumor immunity. PLoS One, 2013, 8, e67512.
130. Yu, F.; Wang, X.; Guo, Z.S.; Bartlett, D.L.; Gottschalk, S.M.; Song, X.-T. T-Cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol. Ther., 2014, 22, 102-111.
131. Fan, R.; Wang, C.; Wang, Y.; Ren, P.; Gan, P.; Ji, H.; Xia, Z.; Hu, S.; Zeng, Q.; Huang, W.; Jiang, Y.; Huang, X. Enhanced antitumoral efficacy and immune response following conditionally replicative adenovirus containing constitutive HSF1 delivery to rodent tumors. J. Transl. Med., 2012, 10, 101.
132. Woller, N.; Knocke, S.; Mundt, B.; Gürlevik, E.; Strüver, N.; Kloos, A.; Boozari, B.; Schache, P.; Manns, M.P.; Malek, N.P.; Sparwasser, T.; Zender, L.; Wirth, T.C.; Kubicka, S.; Kühnel, F. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J. Clin. Invest., 2011, 121, 2570-2582.
133. Zhang, S.-N.; Choi, I.-K.; Huang, J.-H.; Yoo, J.-Y.; Choi, K.-J.; Yun, C.-O. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol. Ther., 2011, 19, 1558-1568.
134. Rommelfanger, D.M.; Wongthida, P.; Diaz, R.M.; Kaluza, K.M.; Thompson, J.M.; Kottke, T.J.; Vile, R.G. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-Cell transfer. Cancer Res., 2012, 72, 4753-4764.
135. Wongthida, P.; Diaz, R.M.; Pulido, C.; Rommelfanger, D.; Galivo, F.; Kaluza, K.; Kottke, T.; Thompson, J.; Melcher, A.; Vile, R. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Hum. Gene Ther., 2011, 22, 1343-1353.
136. Pol, J.G.; Zhang, L.; Bridle, B.W.; Stephenson, K.B.; Rességuier, J.; Hanson, S.; Chen, L.; Kazdhan, N.; Bramson, J.L.; Stojdl, D.F.; Wan, Y.; Lichty, B.D. Maraba virus as a potent oncolytic vaccine vector. Mol. Ther., 2014, 22, 420-429.
137. Bridle, B.W.; Stephenson, K.B.; Boudreau, J.E.; Koshy, S.; Kazdhan, N.; Pullenayegum, E.; Brunellière, J.; Bramson, J.L.; Lichty, B.D.; Wan, Y. Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther., 2010, 18, 1430–1439.
138. Bridle, B.W.; Boudreau, J.E.; Lichty, B.D.; Brunellière, J.; Stephenson, K.; Koshy, S.; Bramson, J.L.; Wan, Y. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol. Ther., 2009, 17, 1814-1821.
139. Kottke, T.; Errington, F.; Pulido, J.; Galivo, F.; Thompson, J.; Wongthida, P.; Diaz, R.M.; Chong, H.; Ilett, E.; Chester, J.; Pandha, H.; Harrington, K.; Selby, P.; Melcher, A.; Vile, R. Broad antigenic coverage induced by vaccination with virus-based cdna libraries cures established tumors. Nat. Med., 2011, 17, 854-859.
140. Rajani, K.; Parrish, C.; Kottke, T.; Thompson, J.; Zaidi, S.; Ilett, L.; Shim, K.G.; Diaz, R.-M.; Pandha, H.; Harrington, K.; Coffey, M.; Melcher, A.; Vile, R. Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol. Ther., 2016, 24(1), 166-174.
141. Zamarin, D.; Holmgaard, R.B.; Subudhi, S.K.; Park, J.S.; Mansour, M.; Palese, P.; Merghoub, T.; Wolchok, J.D.; Allison, J.P. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med., 2014, 6, 226ra32.
142. Engeland, C.E.; Grossardt, C.; Veinalde, R.; Bossow, S.; Lutz, D.; Kaufmann, J.K.; Shevchenko, I.; Umansky, V.; Nettelbeck, D.M.; Weichert, W.; Jäger, D.; von Kalle, C.; Ungerechts, G. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol. Ther., 2014, 22, 1949-1959.
143. Rojas, J.; Sampath, P.; Hou, W.; Thorne, S.H. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin. Cancer Res., 2015.
144. Chen, Y.; DeWeese, T.; Dilley, J.; Zhang, Y.; Li, Y.; Ramesh, N.; Lee, J.; Pennathur-Das, R.; Radzyminski, J.; Wypych, J.; Brignetti, D.; Scott, S.; Stephens, J.; Karpf, D.B.; Henderson, D.R.; Yu, D.C. CV706, a Prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res, 2001, 61, 5453-5460.
145. Martine, L. M. Lamfers; Grill, J.; Dirven, C.M.F.; van Beusechem, V.W.; Geoerger, B.; Den, B.J. van; Alemany, R.; Fueyo, J.; Curiel, D.T.; Vassal, G.; Pinedo, H.M.; Vandertop, W.P.; Gerritsen, W.R. Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliom. Cancer Res., 2002, 62, 5736-5742.
146. Dilley, J.; Reddy, S.; Ko, D.; Nguyen, N.; Rojas, G.; Working, P.; Yu, D.-C. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther., 2005, 12, 715-722.
147. Idema, S.; Lamfers, M.L.M.; van Beusechem, V.W.; Noske, D.P.; Heukelom, S.; Moeniralm, S.; Gerritsen, W.R.; Vandertop, W.P.; Dirven, C.M.F. Ad Delta 24 and the p53-expressing variant ad delta 24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy. J. Gene Med., 2007, 9, 1046-1056.
148. Qian, J.; Yang, J.; Dragovic, A.F.; Abu-Isa, E.; Lawrence, T.S.; Zhang, M. Ionizing radiation-induced adenovirus infection is mediated by dynamin 2. Cancer Res., 2005, 65, 5493-5497.
149. Lamfers, M.L.M.; Idema, S.; Bosscher, L.; Heukelom, S.; Moeniralm, S.; van der Meulen-Muileman, I.H.; Overmeer, R.M.; van der Valk, P.; van Beusechem, V.W.; Gerritsen, W.R.; Vandertop, W.P.; Dirven, C.M.F. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Clin. Cancer Res., 2007, 13, 7451-7458.
150. Liu, C.; Zhang, Y.; Liu, M.M.; Zhou, H.; Chowdhury, W.; Lupold, S.E.; Deweese, T.L.; Rodriguez, R. evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. Int. J. Radiat. Biol., 2010, 86, 220-229.
151. Adusumilli, P.S.; Chan, M.; Hezel, M.; Yu, Z.; Stiles, B.M.; Chou, T.; Rusch, V.W.; Fong, Y. Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma. Ann. Surg. Oncol., 2007, 14, 258-269.
152. Advani, S.J.; Sibley, G.S.; Song, P.Y.; Hallahan, D.E.; Kataoka, Y.; Roizman, B.; Weichselbaum, R.R. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther., 1998, 5, 160-165.
153. Bradley, J.D.; Kataoka, Y.; Advani, S.; Chung, S.M.; Arani, R.B.; Gillespie, G.Y.; Whitley, R.J.; Markert, J.M.; Roizman, B.; Weichselbaum, R.R. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin. Cancer Res., 1999, 5, 1517-1522.
154. Blank, S.V; Rubin, S.C.; Coukos, G.; Amin, K.M.; Albelda, S.M.; Molnar-Kimber, K.L. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum. Gene Ther., 2002, 13, 627-639.
155. Dai, M.-H.; Zamarin, D.; Gao, S.P.; Chou, T.-C.; Gonzalez, L.; Lin, S.-F.; Fong, Y. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br. J. Surg., 2010, 97, 1385-1394.
156. Mezhir, J.J.; Advani, S.J.; Smith, K.D.; Darga, T.E.; Poon, A.P.W.; Schmidt, H.; Posner, M.C.; Roizman, B.; Weichselbaum, R.R. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res., 2005, 65, 9479-9484.
157. Hadjipanayis, C.G.; DeLuca, N.A. Inhibition of DNA repair by a herpes simplex virus vector enhances the radiosensitivity of human glioblastoma cells. Cancer Res., 2005, 65, 5310-5316.
158. Adusumilli, P.S.; Stiles, B.M.; Chan, M.K.; Chou, T.C.; Wong, R.J.; Rusch, V.W.; Fong, Y. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann. Thorac. Surg., 2005, 80, 409-417.
159. Jorgensen, T.J.; Katz, S.; Wittmack, E.K.; Varghese, S.; Todo, T.; Rabkin, S.D.; Martuza, R.L. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia (New York, NY), 2001, 3, 451-456.
160. Advani, S.J.; Markert, J.M.; Sood, R.F.; Samuel, S.; Gillespie, G.Y.; Shao, M.Y.; Roizman, B.; Weichselbaum, R.R. increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther., 2011, 18, 1098-1102.
161. Markert, J.M.; Razdan, S.N.; Kuo, H.-C.; Cantor, A.; Knoll, A.; Karrasch, M.; Nabors, L.B.; Markiewicz, M.; Agee, B.S.; Coleman, J.M.; Lakeman, A.D.; Palmer, C. a; Parker, J.N.; Whitley, R.J.; Weichselbaum, R.R.; Fiveash, J.B.; Gillespie, G.Y. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent gbm demonstrates safety and radiographic responses. Mol. Ther., 2014, 22, 1048-1055.
162. Kyula, J.N.; Khan, A A; Mansfield, D.; Karapanagiotou, E.M.; McLaughlin, M.; Roulstone, V.; Zaidi, S.; Pencavel, T.; Touchefeu, Y.; Seth, R.; Chen, N.G.; Yu, Y.A; Zhang, Q.; Melcher, A.A; Vile, R.G.; Pandha, H.S.; Ajaz, M.; Szalay, A.A; Harrington, K.J. Synergistic cytotoxicity of radiation and oncolytic lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling. Oncogene, 2014, 33, 1700-1712.
163. Buckel, L.; Advani, S.J.; Frentzen, A.; Zhang, Q.; Yu, Y.A.; Chen, N.G.; Ehrig, K.; Stritzker, J.; Mundt, A.J.; Szalay, A.A. Combination of fractionated irradiation with anti-vegf expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium. Int. J. cancer., 2013, 133, 2989-2999.
164. Young, B.A.; Spencer, J.F.; Ying, B.; Toth, K.; Wold, W.S.M. The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the syrian hamster model. Cancer Gene Ther., 2013, 20, 531-537.
165. Geoerger, B.; Grill, J.; Opolon, P.; Morizet, J.; Aubert, G.; Lecluse, Y.; van Beusechem, V.W.; Gerritsen, W.R.; Kirn, D.H.; Vassal, G. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br. J. Cancer, 2003, 89, 577-584.
166. Alajez, N.M.; Mocanu, J.D.; Shi, W.; Chia, M.C.; Breitbach, C.J.; Hui, A.B.Y.; Knowles, S.; Bell, J.C.; Busson, P.; Takada, K.; Lo, K.-W.; O’Sullivan, B.; Gullane, P.; Liu, F.-F. Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma. Clin. Cancer Res., 2008, 14, 4891-4897.
167. Alajez, N.M.; Mocanu, J.D.; Krushel, T.; Bell, J.C.; Liu, F.-F. Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent. Cancer Cell Int., 2012, 12, 27.
168. Advani, S.J.; Buckel, L.; Chen, N.G.; Scanderbeg, D.J.; Geissinger, U.; Zhang, Q.; Yu, Y. A.; Aguilar, R.J.; Mundt, A.J.; Szalay, A. A. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. Clin. Cancer Res., 2012, 18, 2579-2590.
169. Mansfield, D.; Pencavel, T.; Kyula, J.N.; Zaidi, S.; Roulstone, V.; Thway, K.; Karapanagiotou, L.; Khan, A. A.; McLaughlin, M.; Touchefeu, Y.; Seth, R.; Melcher, A.A.; Vile, R.G.; Pandha, H.S.; Harrington, K.J. Oncolytic vaccinia virus and radiotherapy in head and neck cancer. Oral Oncol., 2013, 49, 108-118.
170. Twigger, K.; Vidal, L.; White, C.L.; De Bono, J.S.; Bhide, S.; Coffey, M.; Thompson, B.; Vile, R.G.; Heinemann, L.; Pandha, H.S.; Errington, F.; Melcher, A.A.; Harrington, K.J. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin. Cancer Res., 2008, 14, 912-923.
171. Liu, C.; Sarkaria, J.N.; Petell, C. a; Paraskevakou, G.; Zollman, P.J.; Schroeder, M.; Carlson, B.; Decker, P. a; Wu, W.; James, C.D.; Russell, S.J.; Galanis, E. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin. Cancer Res., 2007, 13, 7155-7165.
172. Touchefeu, Y.; Franken, P.; Harrington, K.J. Radiovirotherapy: principles and prospects in oncology. Curr. Pharm. Des., 2012, 18, 3313-3320.
173. Penheiter, A.R.; Dingli, D.; Bender, C.E.; Russell, S.J.; Carlson, S.K. Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography. J. Gene Med., 2014, 14, 590-597.
174. Hasegawa, K.; Pham, L.; O’Connor, M.K.; Federspiel, M.J.; Russell, S.J.; Peng, K.-W. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin. Cancer Res., 2006, 12, 1868-1875.
175. Msaouel, P.; Iankov, I.D.; Allen, C.; Aderca, I.; Federspiel, M.J.; Tindall, D.J.; Morris, J.C.; Koutsilieris, M.; Russell, S.J.; Galanis, E. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol. Ther., 2009, 17, 2041-2048.
176. Li, H.; Peng, K.-W.; Dingli, D.; Kratzke, R.A; Russell, S.J. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther., 2010, 17, 550-558.
177. Reddi, H. V; Madde, P.; McDonough, S.J.; Trujillo, M. a; Morris, J.C.; Myers, R.M.; Peng, K.W.; Russell, S.J.; McIver, B.; Eberhardt, N.L. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: A novel therapeutic agent allowing noninvasive imaging and radioiodine therapy. Cancer Gene Ther., 2012, 19, 659-665.
178. Li, H.; Peng, K.-W.; Russell, S.J. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy. Hum. Gene Ther., 2012, 23, 295-301.
179. Opyrchal, M.; Allen, C.; Iankov, I.; Aderca, I.; Schroeder, M.; Sarkaria, J.; Galanis, E. effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum. Gene Ther., 2012, 23, 419-427.
180. Liu, Y.-P.; Wang, J.; Avanzato, V.A.; Bakkum-Gamez, J.N.; Russell, S.J.; Bell, J.C.; Peng, K.-W. Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol. Oncol., 2014, 132, 722-729.
181. Hutzen, B.; Pierson, C.R.; Russell, S.J.; Galanis, E.; Raffel, C.; Studebaker, A.W. Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine. BMC Cancer, 2012, 12, 508.
182. Miller, A.; Russell, S.J. The use of the nis reporter gene for optimizing oncolytic virotherapy. Expert Opin. Biol. Ther., 2015, 2598, 1-18.
183. Goel, A.; Carlson, S.K.; Classic, K.L.; Greiner, S.; Naik, S.; Power, A.T.; Bell, J.C.; Russell, S.J. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(??51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood, 2007, 110, 2342-2350.
184. Liu, Y.-P.; Steele, M.B.; Suksanpaisan, L.; Federspiel, M.J.; Russell, S.J.; Peng, K.W.; Bakkum-Gamez, J.N. oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. Gynecol. Oncol., 2014, 132, 194-202.
185. Haddad, D.; Chen, N.G.; Zhang, Q.; Chen, C.-H.; Yu, Y.A.; Gonzalez, L.; Carpenter, S.G.; Carson, J.; Au, J.; Mittra, A.; Gonen, M.; Zanzonico, P.B.; Fong, Y.; Szalay, A.A. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. J. Transl. Med., 2011, 9, 36.
186. Haddad, D.; Zanzonico, P.B.; Carlin, S.; Chen, C.-H.; Chen, N.G.; Zhang, Q.; Yu, Y.A.; Longo, V.; Mojica, K.; Aguilar, R.J.; Szalay, A.A.; Fong, Y. A Vaccinia virus encoding the human sodium iodide symporter facilitates long-term image monitoring of virotherapy and targeted radiotherapy of pancreatic cancer. J. Nucl. Med., 2012, 53, 1933-1942.
187. Jun, K.-H.; Gholami, S.; Song, T.-J.; Au, J.; Haddad, D.; Carson, J.; Chen, C.-H.; Mojica, K.; Zanzonico, P.; Chen, N.G.; Zhang, Q.; Szalay, A.; Fong, Y. A novel oncolytic viral therapy and imaging technique for gastric cancer using a genetically engineered vaccinia virus carrying the human sodium iodide symporter. J. Exp. Clin. Cancer Res., 2014, 33, 2.
188. Yoon, A.-R.; Kim, J.-H.; Lee, Y.-S.; Kim, H.; Yoo, J.-Y.; Sohn, J.-H.; Park, B.-W.; Yun, C.-O. Markedly enhanced cytolysis by e1b-19kd-deleted oncolytic adenovirus in combination with cisplatin. Hum. Gene Ther., 2006, 17, 379-390.
189. Cheong, S.C.; Wang, Y.; Meng, J.-H.; Hill, R.; Sweeney, K.; Kirn, D.; Lemoine, N.R.; Halldén, G. E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther., 2008, 15, 40-50.
190. Adhim, Z.; Lin, X.; Huang, W.; Morishita, N.; Nakamura, T.; Yasui, H.; Otsuki, N.; Shigemura, K.; Fujisawa, M.; Nibu, K.; Shirakawa, T. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma. Cancer Gene Ther., 2012, 19, 144-152.
191. Khuri, F.R.; Nemunaitis, J.; Ganly, I.; Arseneau, J.; Tannock, I.F.; Romel, L.; Gore, M.; Ironside, J.; MacDougall, R.H.; Heise, C.; Randlev, B.; Gillenwater, A.M.; Bruso, P.; Kaye, S.B.; Hong, W.K.; Kirn, D.H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 2000, 6, 879-885.
192. Xu, J.; Mo, Y.; Wang, X.; Liu, J.; Zhang, X.; Wang, J.; Hu, L.; Yang, C.; Chen, L.; Wang, Y. conditionally replicative adenovirus-based Mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin. J. Gastroenterol., 2013, 48, 203-213.
193. Alonso, M.M.; Gomez-Manzano, C.; Bekele, B.N.; Yung, W.K.A.; Fueyo, J. Adenovirus-based strategies overcome temozolomide resistance by silencing the o6-methylguanine-DNA methyltrans-ferase promoter. Cancer Res., 2007, 67, 11499-11504.
194. Liikanen, I.; Ahtiainen, L.; Hirvinen, M.L.M.; Bramante, S.; Cerullo, V.; Nokisalmi, P.; Hemminki, O.; Diaconu, I.; Pesonen, S.; Koski, A.; Kangasniemi, L.; Pesonen, S.K.; Oksanen, M.; Laasonen, L.; Partanen, K.; Joensuu, T.; Zhao, F.; Kanerva, A.; Hemminki, A. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol. Ther., 2013, 21, 1212-1223.
195. Gomez-Manzano, C.; Alonso, M.M.; Yung, W.K.A.; McCormick, F.; Curiel, D.T.; Lang, F.F.; Jiang, H.; Bekele, B.N.; Zhou, X.; Alemany, R.; Fueyo, J. Delta-24 increases the expression and activity of topoisomerase i and enhances the antiglioma effect of irinotecan. Clin. Cancer Res., 2006, 12, 556-562.
196. Ingemarsdotter, C.K.; Baird, S.K.; Connell, C.M.; Öberg, D.; Halldén, G.; McNeish, I. A. Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene, 2010, 29, 6051-6063.
197. Rein, D.T.; Volkmer, A.; Beyer, I.M.; Curiel, D.T.; Janni, W.; Dragoi, A.; Hess, A.P.; Maass, N.; Baldus, S.E.; Bauerschmitz, G.; Breidenbach, M. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus. Gynecol. Oncol., 2011, 123, 138-146.
198. Ma, G.; Kawamura, K.; Li, Q.; Okamoto, S.; Suzuki, N.; Kobayashi, H.; Liang, M.; Tada, Y.; Tatsumi, K.; Hiroshima, K.; Shimada, H.; Tagawa, M. Combinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma. Cancer Gene Ther., 2010, 17, 803-813.
199. Ye, W.; Liu, R.; Pan, C.; Jiang, W.; Zhang, L.; Guan, Z.; Wu, J.; Ying, X.; Li, L.; Li, S.; Tan, W.; Zeng, M.; Kang, T.; Liu, Q.; Thomas, G.R.; Huang, M.; Deng, W.; Huang, W. Multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma. Mol. Ther., 2014, 22, 1221-1229.
200. Adusumilli, P.S.; Chan, M.K.; Chun, Y.S.; Hezel, M.; Chou, T.C.; Rusch, V.W.; Fong, Y. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol. Ther, 2006, 5, 48-53.
201. Kulu, Y.; Kawasaki, H.; Donahue, J.M.; Kasuya, H.; Cusack, J.C.; Choi, E.W.; Kuruppu, D.K.; Fuchs, B.C.; Tanabe, K.K. Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis. Cancer Gene Ther., 2013, 20, 133-140.
202. Heinemann, L.; Simpson, G.R.; Boxall, A.; Kottke, T.; Relph, K.L.; Vile, R.; Melcher, A.; Prestwich, R.; Harrington, K.J.; Morgan, R.; Pandha, H.S. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer, 2011, 11, 221.
203. Huang, B.; Sikorski, R.; Kirn, D.H.; Thorne, S.H. Synergistic antitumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther., 2011, 18, 164-172.
204. Sung, C.-K.; Choi, B.; Wanna, G.; Genden, E.M.; Woo, S.L.C.; Shin, E.J. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Laryngoscope, 2008, 118, 237-242.
205. Workenhe, S.T.; Pol, J.G.; Lichty, B.D.; Cummings, D.T.; Mossman, K.L. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunol. Res., 2013, 1, 309-319.
206. Bagheri, N.; Shiina, M.; Lauffenburger, D.A; Korn, W.M. A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition. PLoS Comput. Biol., 2011, 7, e1001085.
207. Nguyên, T.L.-A.; Abdelbary, H.; Arguello, M.; Breitbach, C.; Leveille, S.; Diallo, J.-S.; Yasmeen, A.; Bismar, T.A.; Kirn, D.; Falls, T.; Snoulten, V.E.; Vanderhyden, B.C.; Werier, J.; Atkins, H.; Vähä-Koskela, M.J.V.; Stojdl, D.F.; Bell, J.C.; Hiscott, J. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 14981-14986.
208. Shulak, L.; Beljanski, V.; Chiang, C.; Dutta, S.M.; Van Grevenynghe, J.; Belgnaoui, S.M.; Nguyên, T.L.-A.; Di Lenardo, T.; Semmes, O.J.; Lin, R.; Hiscott, J. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy. J. Virol., 2014, 88, 2927-2940.
209. Li, J.; Bonifati, S.; Hristov, G.; Marttila, T.; Valmary-Degano, S.; Stanzel, S.; Schnölzer, M.; Mougin, C.; Aprahamian, M.; Grekova, S.P.; Raykov, Z.; Rommelaere, J.; Marchini, A. Synergistic combination of valproic acid and oncolytic parvovirus h-1pv as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol. Med., 2013, 5, 1537-1555.
210. Liu, T.-C.; Castelo-Branco, P.; Rabkin, S.D.; Martuza, R.L. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol. Ther., 2008, 16, 1041-1047.
211. Katsura, T.; Iwai, S.; Ota, Y.; Shimizu, H.; Ikuta, K.; Yura, Y. The effects of trichostatin a on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther., 2009, 16, 237-245.
212. Cody, J.J.; Markert, J.M.; Hurst, D.R. Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. PLoS One, 2014, 9, e92919.
213. Otsuki, A.; Patel, A.; Kasai, K.; Suzuki, M.; Kurozumi, K.; Chiocca, E.A.; Saeki, Y. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol. Ther., 2008, 16, 1546-1555.
214. MacTavish, H.; Diallo, J.S.; Huang, B.; Stanford, M.; Le Boeuf, F.; De Silva, N.; Cox, J.; Simmons, J.G.; Guimond, T.; Falls, T.; McCart, A.J.; Atkins, H.; Breitbach, C.; Kirn, D.; Thorne, S.; Bell, J.C. Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One, 2010, 5, 1-9.
215. Watanabe, T.; Hioki, M.; Fujiwara, T.; Nishizaki, M.; Kagawa, S.; Taki, M.; Kishimoto, H.; Endo, Y.; Urata, Y.; Tanaka, N.; Fujiwara, T. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp. Cell Res., 2006, 312, 256-265.
216. Bieler, A.; Mantwill, K.; Dravits, T.; Bernshausen, A.; Glockzin, G.; Kohler-Vargas, N.; Lage, H.; Gansbacher, B.; Holm, P.S. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther, 2006, 17, 55-70.
217. Höti, N.; Chowdhury, W.; Hsieh, J.-T.; Sachs, M.D.; Lupold, S.E.; Rodriguez, R. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol. Ther., 2006, 14, 768-778.
218. Xu, W.S.; Parmigiani, R.B.; Marks, P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene, 2007, 26, 5541-5552.
219. Bridle, B.W.; Chen, L.; Lemay, C.G.; Diallo, J.-S.; Pol, J.; Nguyen, A.; Capretta, A.; He, R.; Bramson, J.L.; Bell, J.C.; Lichty, B.D.; Wan, Y. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol. Ther., 2013, 21, 887-894.
220. Jordan, C.T.; Guzman, M.L.; Noble, M. Cancer stem cells. N. Engl. J. Med., 2006, 355, 1253-1261.
221. Magee, J.A.; Piskounova, E.; Morrison, S.J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell, 2012, 21, 283-296.
222. Frank, N.Y.; Schatton, T.; Frank, M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest., 2010, 120, 41-50.
223. Cripe, T.P.; Wang, P.-Y.; Marcato, P.; Mahller, Y.Y.; Lee, P.W. Targeting cancer-initiating cells with oncolytic viruses. Mol. Ther., 2009, 17, 1677-1682.
224. Short, J.J.; Curiel, D.T. Oncolytic adenoviruses targeted to cancer stem cells. Mol. Cancer Ther., 2009, 8, 2096-2102.
225. Smith, T.T.; Roth, J.C.; Friedman, G.K.; Gillespie, G.Y. Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virother., 2014, 2014, 21-33.
226. Eriksson, M.; Guse, K.; Bauerschmitz, G.; Virkkunen, P.; Tarkkanen, M.; Tanner, M.; Hakkarainen, T.; Kanerva, A.; Desmond, R.A.; Pesonen, S.; Hemminki, A. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24–/low cells. Mol. Ther., 2007, 15, 2088-2093.
227. Bauerschmitz, G.J.; Ranki, T.; Kangasniemi, L.; Ribacka, C.; Eriksson, M.; Porten, M.; Herrmann, I.; Ristimäki, A.; Virkkunen, P.; Tarkkanen, M.; Hakkarainen, T.; Kanerva, A.; Rein, D.; Pesonen, S.; Hemminki, A. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res., 2008, 68, 5533-5539.
228. Jiang, H.; Gomez-Manzano, C.; Aoki, H.; Alonso, M.M.; Kondo, S.; McCormick, F.; Xu, J.; Kondo, Y.; Bekele, B.N.; Colman, H.; Lang, F.F.; Fueyo, J. Examination of the therapeutic potential of delta-24-rgd in brain tumor stem cells: role of autophagic cell death. J. Natl. Cancer Inst., 2007, 99, 1410-1414.
229. Skog, J.; Edlund, K.; Bergenheim, A.T.; Wadell, G. Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells. Mol. Ther., 2007, 15, 2140-2145.
230. Zhang, X.; Komaki, R.; Wang, L.; Fang, B.; Chang, J.Y. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin. Cancer Res., 2008, 14, 2813-2823.
231. Wakimoto, H.; Kesari, S.; Farrell, C.J.; Curry, W.T.; Zaupa, C.; Aghi, M.; Kuroda, T.; Stemmer-Rachamimov, A.; Shah, K.; Liu, T.-C.; Jeyaretna, D.S.; Debasitis, J.; Pruszak, J.; Martuza, R.L.; Rabkin, S.D. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res., 2009, 69, 3472-3481.
232. Friedman, G.K.; Langford, C.P.; Coleman, J.M.; Cassady, K.A; Parker, J.N.; Markert, J.M.; Yancey Gillespie, G. Engineered herpes simplex viruses efficiently infect and kill CD133+ Human glioma xenograft cells that express CD111. J. Neurooncol., 2009, 95, 199-209.
233. Friedman, G.K.; Haas, M.C.; Kelly, V.M.; Markert, J.M.; Gillespie, G.Y.; Cassady, K.A. Hypoxia moderates γ134.5-deleted herpes simplex virus oncolytic activity in human glioma xenoline primary cultures. Transl. Oncol., 2012, 5, 200-207.
234. Sgubin, D.; Wakimoto, H.; Kanai, R.; Rabkin, S.D.; Martuza, R.L. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl. Med., 2012, 1, 322-332.
235. Kanai, R.; Rabkin, S.D.; Yip, S.; Sgubin, D.; Zaupa, C.M.; Hirose, Y.; Louis, D.N.; Wakimoto, H.; Martuza, R.L. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J. Natl. Cancer Inst., 2012, 104, 42-55.
236. Kanai, R.; Wakimoto, H.; Martuza, R.L.; Rabkin, S.D. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin. Cancer Res., 2011, 17, 3686-3696.
237. Zhuang, X.; Zhang, W.; Chen, Y.; Han, X.; Li, J.; Zhang, Y.Y.; Zhang, S.; Liu, B. Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1. BMC Cancer, 2012, 12, 549.
238. Cheema, T.A.; Kanai, R.; Kim, G.W.; Wakimoto, H.; Passer, B.; Rabkin, S.D.; Martuza, R.L. Enhanced antitumor efficacy of low-dose etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin. Cancer Res., 2011, 17, 7383-7393.
239. Cheema, T.A.; Wakimoto, H.; Fecci, P.E.; Ning, J.; Kuroda, T.; Jeyaretna, D.S.; Martuza, R.L.; Rabkin, S.D. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc. Natl. Acad. Sci. U. S. A., 2013, 110, 12006-12011.
240. Allen, C.; Opyrchal, M.; Aderca, I.; Schroeder, M.A.; Sarkaria, J.N.; Domingo, E.; Federspiel, M.J.; Galanis, E. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. Gene Ther., 2013, 20, 444-449.
241. Bach, P.; Abel, T.; Hoffmann, C.; Gal, Z.; Braun, G.; Voelker, I.; Ball, C.R.; Johnston, I.C.D.; Lauer, U.M.; Herold-Mende, C.; Mühlebach, M.D.; Glimm, H.; Buchholz, C.J. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res., 2013, 73, 865-874.
242. Friedrich, K.; Hanauer, J.R.; Prüfer, S.; Münch, R.C.; Völker, I.; Filippis, C.; Jost, C.; Hanschmann, K.-M.; Cattaneo, R.; Peng, K.-W.; Plückthun, A.; Buchholz, C.J.; Cichutek, K.; Mühlebach, M.D. DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol. Ther., 2013, 21, 849-859.
243. Parato, K.A.; Breitbach, C.J.; Le Boeuf, F.; Wang, J.; Storbeck, C.; Ilkow, C.; Diallo, J.-S.; Falls, T.; Burns, J.; Garcia, V.; Kanji, F.; Evgin, L.; Hu, K.; Paradis, F.; Knowles, S.; Hwang, T.-H.; Vanderhyden, B.C.; Auer, R.; Kirn, D.H.; Bell, J.C. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol. Ther., 2012, 20, 749-758.
244. Wang, H.; Chen, N.G.; Minev, B.R.; Szalay, A.A. Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. J. Transl. Med., 2012, 10, 167.